Supp Fig1 Version 1
Fig. S1 Liver cell proliferation, resident macrophage and leucocyte numbers upon Galunisertib treatment in 26-weeks-old Abcb4ko mice. a) Representative images of Ki-67 (proliferation marker), F4/80 (resident macrophages) and CD45 (leukocyte common marker) positive signals in liver tissues upon Galunisertib or vehicle administration. Scale bars are 100 µm. b and c) show numbers of proliferating hepatocytes and non-parenchymal cells, as indicated by Ki-67 positivity. d and e) quantification of F4/80 positive areas and number of CD45 positive cells, among different groups. Data are means ± SD of 5–7 mice per group. N.S.: P > 0.05; **: P < 0.01 compared with untreated livers unless otherwise indicated. (PPTX 4035 KB)
Export PNG
Download
Creators and Submitter
Views: 955 Downloads: 0
Created: 13th Dec 2021 at 09:27
TagsThis item has not yet been tagged.
AttributionsNone
Version History
Version 1 (earliest) Created 13th Dec 2021 at 09:27 by Seddik Hammad
No revision comments
Related items
Projects: LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM network, LiSyM PALs, LiSyM-Krebs Partnering, C-TIP-HCC network
Institutions: Molecular Hepatology - Dept of Medicine II - Medical Faculty Mannheim - Heidelberg University
Liver Systems Medicine : striving to develop non-invasive methods for diagnosing and treating NAFLD by combining mathematical modeling and biological research. LiSyM, is a multidisciplinary research network, in which molecular and cell biologists, clinical researchers, pharmacologists and experts in mathematical modeling examine the liver in its entirety. LiSyM research focuses on the metabolic liver disease non-alcoholic fatty liver disease (NAFLD), which includes non-alcoholic steatohepatitis ...
Projects: LiSyM Core Infrastructure and Management (LiSyM-PD), LiSyM Pillar I: Early Metabolic Injury (LiSyM-EMI), LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM Pillar IV: Liver Function Diagnostics (LiSyM-LiFuDi), Model Guided Pharmacotherapy In Chronic Liver Disease (LiSyM-MGP), Molecular Steatosis - Imaging & Modeling (LiSyM-MSIM), The Hedgehog Signalling Pathway (LiSyM-JGMMS), Multi-Scale Models for Personalized Liver Function Tests (LiSyM-MM-PLF), LiSyM PALs, Project Management PTJ, LiSyM network, LiSyM Scientific Leadership Team (LiSyM-LT)
Web page: https://www.lisym.org/
In one in five people with NAFLD, the functioning liver cells, the hepatocytes, are replaced by connective tissue. Eventually this fibrosis becomes irreversible. In this state the liver is like a ‘scar that never heals’. Through it, the liver loses many of its vital functions. LiSyM-Pillar II wants to know more about which factors promote fibrosis and the conditions under which fibrosis becomes irreversible How can fibrosis be diagnosed as early as possible? Researchers in the pillar are also ...
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org/our-work/pillar-research
Start date: 1st Jan 2016
Abstract (Expand)
Authors: Seddik Hammad, Elisabetta Cavalcanti, Julia Werle, Maria Lucia Caruso, Anne Dropmann, Antonia Ignazzi, Matthias Philip Ebert, Steven Dooley, Gianluigi Giannelli
Date Published: 28th May 2018
Publication Type: Not specified
